Compare ABR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | WVE |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.7M | 673.9M |
| IPO Year | 2003 | 2015 |
| Metric | ABR | WVE |
|---|---|---|
| Price | $2.86 | $3.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $3.25 | ★ $17.68 |
| AVG Volume (30 Days) | ★ 7.3M | 2.8M |
| Earning Date | 10-30-2026 | 10-27-2026 |
| Dividend Yield | ★ 23.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | $19.15 |
| Revenue Next Year | $3.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $2.53 | $3.04 |
| 52 Week High | $11.93 | $21.73 |
| Indicator | ABR | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 30.57 | 32.30 |
| Support Level | $2.53 | $3.04 |
| Resistance Level | $5.38 | $4.07 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 35.75 | 24.12 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.